Intercure Ltd. logo

Intercure Ltd. (INCR)

Market Closed
1 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
1. 48
+0.01
+0.68%
$
70.27M Market Cap
- P/E Ratio
0% Div Yield
23,300 Volume
- Eps
$ 1.47
Previous Close
Day Range
1.46 1.5
Year Range
1.17 2.62
Want to track INCR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

INCR closed Tuesday higher at $1.48, an increase of 0.68% from Monday's close, completing a monthly increase of 0.68% or $0.01. Over the past 12 months, INCR stock lost -8.07%.
INCR is not paying dividends to its shareholders.
The last earnings report, released on Dec 13, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.08%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

INCR Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025

InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025

2024 results were affected by damages to our southern facility caused by the terrorist attack on October 7, 2023, and the continued war in Gaza.  InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to the southern facility.

Prnewswire | 2 months ago
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

NEW YORK and HERZLIYA, Israel , Feb. 12, 2025 /PRNewswire/ -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), announces today that Mr.

Prnewswire | 4 months ago
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-war. The funding includes investments from key shareholders of the company, including CEO Alexander Rabinovich, as well as lead investors Yaron Yakobi and Tzahi Hagag who will become significant shareholders.

Prnewswire | 6 months ago

Intercure Ltd. Dividends

INCR is not paying dividends to its shareholders.

Intercure Ltd. Earnings

13 Dec 2024 Date
-
Cons. EPS
-
EPS
23 May 2024 Date
-
Cons. EPS
-
EPS
1 Apr 2024 Date
-
Cons. EPS
-
EPS
28 Nov 2023 Date
0.03
Cons. EPS
-
EPS
21 Nov 2023 Date
0.03
Cons. EPS
-
EPS
INCR is not paying dividends to its shareholders.
13 Dec 2024 Date
-
Cons. EPS
-
EPS
23 May 2024 Date
-
Cons. EPS
-
EPS
1 Apr 2024 Date
-
Cons. EPS
-
EPS
28 Nov 2023 Date
0.03
Cons. EPS
-
EPS
21 Nov 2023 Date
0.03
Cons. EPS
-
EPS

Intercure Ltd. (INCR) FAQ

What is the stock price today?

The current price is $1.48.

On which exchange is it traded?

Intercure Ltd. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is INCR.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 70.27M.

Has Intercure Ltd. ever had a stock split?

No, there has never been a stock split.

Intercure Ltd. Profile

Drug Manufacturers - Specialty & Generic Industry
Healthcare Sector
Alexander Rabinovich CEO
NASDAQ (NMS) Exchange
M549GJ111 Cusip
IL Country
320 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

InterCure Ltd. is a prominent player in the medical cannabis industry, extending its footprint beyond its home country Israel to serve international markets. Founded in 1994 and based in Herzliya, Israel, the company has carved a niche in researching, cultivating, producing, and distributing pharmaceutical-grade cannabis and cannabis-based products tailored for medical applications. Besides its core operations in the cannabis sector, InterCure Ltd. also places strategic investments in the biomed sector, reflecting its broader vision in healthcare and medical innovations.

Products and Services

  • Dried Cannabis Inflorescences: These are high-quality cannabis flowers cultivated under stringent controls to ensure pharmaceutical-grade quality. Used primarily for their therapeutic properties, they serve patients who rely on medical cannabis for relief from various conditions.
  • Cannabis Extract Mixed with Oil: This product combines potent cannabis extracts with carrier oils to enhance bioavailability and ease of use. It's designed for patients seeking precise dosage and a more convenient consumption method than traditional flower products.

Contact Information

Address: 85 Medinat ha-Yehudim Street
Phone: 972 7 7460 5012